CYBN Stock Overview
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cybin Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.41 |
52 Week High | US$0.74 |
52 Week Low | US$0.21 |
Beta | 0.93 |
1 Month Change | 18.82% |
3 Month Change | 0.85% |
1 Year Change | 8.82% |
3 Year Change | -63.41% |
5 Year Change | n/a |
Change since IPO | -40.40% |
Recent News & Updates
Recent updates
Shareholder Returns
CYBN | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 1.5% | 1.2% | 0.4% |
1Y | 8.8% | 25.8% | 28.8% |
Return vs Industry: CYBN underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: CYBN underperformed the US Market which returned 28.8% over the past year.
Price Volatility
CYBN volatility | |
---|---|
CYBN Average Weekly Movement | 10.9% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYBN's share price has been volatile over the past 3 months.
Volatility Over Time: CYBN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 50 | Doug Drysdale | https://www.cybin.com |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.
Cybin Inc. Fundamentals Summary
CYBN fundamental statistics | |
---|---|
Market cap | US$326.82m |
Earnings (TTM) | -US$52.02m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs CYBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CYBN income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$70.45m |
Earnings | -CA$70.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.093 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CYBN perform over the long term?
See historical performance and comparison